FUNDACION AG;CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS);CONSIGLIO NAZIONALE DELLE RICERCHE – NATIONAL RESEARCH COUNCIL ITALY;INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
The present invention relates to the treatment of a tumor selected from the group consisting of pancreatic cancer, liver cancer, melanoma, colon cancer, glioblastoma, osteosarcoma, prostate cancer and breast cancer, more particularly pancreatic cancer. The inventors found a novel family compounds of formula (I) able to treat a variety of cancers by inhibiting NUPR1, a stress-inducible 82-amino-acid-long, intrinsically disordered member of the AT-hook family of chromatin proteins. Thus, the present invention relates to a compound of formula (I) for its use in the treatment of a tumor selected from the group consisting of pancreatic cancer, liver cancer, melanoma, colon cancer, glioblastoma, osteosarcoma, prostate cancer and breast cancer. In particular, the inventors tested compounds of formula (I) on four well characterized primary pancreatic cancer-derived cells 02.063 and LIPC (Basal subtype), Foic8b (derived from a liver metastasis) and HN14 (Classical subtype), as well as on other cellular lines derived from different tumors, i.e. U87 (glioblastoma), A375 and B16 (melanoma), U20S and SaOS (osteosarcoma), HT29, SK-CO-l and LS174T (colon cancer), HepG2 (hepatocarcinoma), PC3 (prostate) and MDA-MB-231 (breast cancer). The compounds per se are also claimed.La présente invention concerne le traitement d'une tumeur choisie dans le groupe constitué par le cancer du pancréas, le cancer du foie, le mélanome, le cancer du côlon, le glioblastome, l'ostéosarcome, le cancer de la prostate et le cancer du sein, plus particulièrement le cancer du pancréas. Les inventeurs ont découvert une nouvelle famille de composés de formule (I) capables de traiter une variété de cancers par inhibition de NUPR1, un élément intrinsèquement désordonné de 82 acides aminés longs inductible par le stress de la famille des crochets AT des protéines de la chromatine. Ainsi, la présente invention concerne un composé de formule (I) pour son utilisation dans le traitement d'une tumeur choisie dans le
